PMV Pharmaceuticals Inc

NASDAQ:PMVP   4:00:00 PM EDT
9.99
+0.10 (+1.01%)
4:01:13 PM EDT: $9.99 0.00 (0.00%)
Earnings Announcements

Pmv Pharmaceuticals Reports Third Quarter Results

Published: 11/08/2022 14:39 GMT
PMV Pharmaceuticals Inc (PMVP) - Pmv Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights.
Phase 1b Combination Trial With Merck Evaluating Pc14586 With Keytruda(®) (pembrolizumab) on Track to Initiate in 2022.
Qtrly Loss per Share $0.40.
Q3 Earnings per Share View $-0.42 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.44

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.46

More details on our Analysts Page.